Treatment of Recalcitrant Dermatomyositis with Efalizumab

Huber, Andrea; Gaffal, Evelyn; Bieber, Thomas; Tüting, Thomas; Wenzel, Joerg

doi:10.2340/00015555-0058

Cited by 23 publications

(12 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prior to being removed from the market in the spring of 2009 for a potential increased risk of the demyelinating disease progressive multifocal leukoencephalopathy, efalizumab had shown promise in at least one case report of refractory DM [90]. After failing to improve on methotrexate and prednisolone, the patient in this case had improved skin disease after being started on efalizumab 1 mg/kg/week combined with prednisolone 40 mg/day.…”

Section: Efalizumabmentioning

confidence: 83%

Dermatomyositis: current and future treatments

Vleugels

Callen

2009

Expert Review of Dermatology

View full text Add to dashboard Cite

Section: Efalizumabmentioning

confidence: 83%

Dermatomyositis: current and future treatments

Vleugels

Callen

2009

Expert Review of Dermatology

View full text Add to dashboard Cite

“…Observations from individual case reports and small case series suggest that for skin disease, hydroxychloroquine [ [ 52 ], efalizumab [ 53 ], and antiestrogen medications [ 54 ] are effective corticosteroid-sparing agents. A retrospective series suggests that patients with dermatomyositis may have an increased risk of hydroxychloroquine reactions [ 55 ].…”

Section: Cutaneous Diseasementioning

confidence: 97%

Immunomodulatory treatment for dermatomyositis

Callen

2008

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

Dermatomyositis and polymyositis are classified as members of idiopathic inflammatory myopathies. It has recently become evident that the pathogenesis of the muscle disease for these two entities is likely not the same. Despite this observation, therapies directed at the muscle disease are similar, although therapy for the skin differs slightly. Corticosteroids remain the initial approach to management. The systemic dose of corticosteroids needed to control the disease, particularly the skin disease, is quite high; therefore, most authorities add a corticosteroid-sparing agent early. Some patients will naturally "burn out" the inflammatory component of their disease, but many have continuing disease activity that requires maintenance therapy. In this article, we briefly define the disease state of dermatomyositis, discuss the associated systemic manifestations, and update the selection and evaluation of immunomodulatory, corticosteroid-sparing agents.

show abstract

“…However, there are not enough data to make clear judgments about the use of these. Rapamycin, 98 efalizumab, 117 and tacrolimus, 118,119 may eventually have a place in the treatment of DM.…”

Section: Biologicsmentioning

confidence: 99%